Finasteride

• CAT Number: A001008
• CAS Number: 98319-26-7
• Molecular Formula: C23H36N2O2
• Molecular Weight: 372.5
• Purity: ≥95%
• Target: 5-alpha Reductase
• Solubility: >14.7mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
• InChIKey: DBEPLOCGEIEOCV-WSBQPABSSA-N
• SMILES: CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C

Finasteride is a medication used for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB). It is a type II and type III 5α-reductase inhibitor; 5α-reductase, an enzyme, converts testosterone to dihydrotestosterone (DHT).

Reference

1: Kaplan SA. Re: Long-Term Consequences of Finasteride vs Placebo in the
Prostate Cancer Prevention Trial. J Urol. 2018 Jan;199(1):7-8. doi:
10.1016/j.juro.2017.09.132. Epub 2017 Oct 9. PubMed PMID: 29310201.

2: Meijer M, Thygesen LC, Green A, Emneus M, Brasso K, Iversen P, Pukkala E,
Bolin K, Stavem K, Ersbøll AK. Finasteride treatment and male breast cancer: a
register-based cohort study in four Nordic countries. Cancer Med. 2017 Dec 13.
doi: 10.1002/cam4.1273. [Epub ahead of print] PubMed PMID: 29239131.

3: Li L, Kang YX, Ji XM, Li YK, Li SC, Zhang XJ, Cui HX, Shi GM. Finasteride
inhibited brain dopaminergic system and open-field behaviors in adolescent male
rats. CNS Neurosci Ther. 2017 Dec 6. doi: 10.1111/cns.12781. [Epub ahead of
print] PubMed PMID: 29214729.

4: Zhao R, Wang X, Jiang C, Shi F, Zhu Y, Yang B, Zhuo J, Jing Y, Luo G, Xia S,
Han B. Finasteride accelerates prostate wound healing after thulium laser
resection through DHT and AR signalling. Cell Prolif. 2017 Nov 30. doi:
10.1111/cpr.12415. [Epub ahead of print] PubMed PMID: 29194865.

5: Ahmed TA, El-Say KM, Hosny KM, Aljaeid BM. Development of optimized
self-nanoemulsifying lyophilized tablets (SNELTs) to improve finasteride clinical
pharmacokinetic behavior. Drug Dev Ind Pharm. 2017 Nov 29:1-10. doi:
10.1080/03639045.2017.1405977. [Epub ahead of print] PubMed PMID: 29139305.

6: Fouda AM, Bazeed AM. Hematuria and Hematospermia Associated with the Use of
Finasteride for the Treatment of Androgenic Alopecia: A Case Report. Drug Saf
Case Rep. 2017 Oct 31;4(1):14. doi: 10.1007/s40800-017-0059-7. PubMed PMID:
29090364; PubMed Central PMCID: PMC5663988.

7: Wilson V, Siram K, Rajendran S, Sankar V. Development and evaluation of
finasteride loaded ethosomes for targeting to the pilosebaceous unit. Artif Cells
Nanomed Biotechnol. 2017 Oct 31:1-10. doi: 10.1080/21691401.2017.1396221. [Epub
ahead of print] PubMed PMID: 29087225.

8: Soni KK, Shin YS, Choi BR, Karna KK, Kim HK, Lee SW, Kim CY, Park JK.
Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis:
inositol requiring kinase 1 and c-Jun N-terminal kinase pathway. Drug Des Devel
Ther. 2017 Oct 11;11:2969-2979. doi: 10.2147/DDDT.S140543. eCollection 2017.
PubMed PMID: 29066868; PubMed Central PMCID: PMC5644560.

9: Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model
induced by oral administration of finasteride. Mol Med Rep. 2017
Dec;16(6):8763-8770. doi: 10.3892/mmr.2017.7754. Epub 2017 Oct 10. PubMed PMID:
29039509.

10: Kaplan SA. Re: Rates of Prostate Surgery and Acute Urinary Retention for
Benign Prostatic Hyperplasia in Men Treated with Dutasteride or Finasteride. J
Urol. 2017 Oct;198(4):719-721. doi: 10.1016/j.juro.2017.07.003. Epub 2017 Jul 7.
PubMed PMID: 28905745.